Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
Status:
Completed
Trial end date:
2019-08-15
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if lirilumab in combination with
rituximab can help to control either CLL or Small lymphocytic lymphoma (SLL). The safety of
the drug combination will also be studied.